Phase I and pharmacokinetic study of low-dose, three-times daily oral etoposide in patients with refractory solid tumors

被引：0
|
作者：
Schwartsmann, G
Di Leone, L
Caldas, APF
Campos, O
Cancela, AI
Viegas, MAV
Mans, DRA
机构：
[1] UFRGS, HCPA, S Amer Off Anticanc Drug Dev SOAD, Porto Alegre, RS, Brazil
[2] ULBRA, Lutheran Hosp, Porto Alegre, RS, Brazil
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
660
引用
收藏
页码：138 / 138
页数：1
相关论文
共 50 条
  • [21] Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors
    Patnaik, A
    Warner, E
    Michael, M
    Egorin, MJ
    Moore, MJ
    Siu, LL
    Fracasso, PM
    Rivkin, S
    Kerr, I
    Litchman, M
    Oza, AM
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (21) : 3677 - 3689
  • [22] Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors
    Siu, Lillian L.
    Pili, Roberto
    Duran, Ignacio
    Messersmith, Wells A.
    Chen, Eric X.
    Sullivan, Rana
    MacLean, Martha
    King, Serina
    Brown, Shirley
    Reid, Gregory K.
    Li, Zuomei
    Kalita, Ann M.
    Laille, Eric J.
    Besterman, Jeffrey M.
    Martell, Robert E.
    Carducci, Michael A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (12) : 1940 - 1947
  • [23] Phase I and pharmacokinetic study of anhydrovinblastine every 3 weeks in patients with refractory solid tumors
    Ramnath, N
    Schwartz, GN
    Smith, P
    Bong, D
    Kanter, P
    Berdzik, J
    Creaven, PJ
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 51 (03) : 227 - 230
  • [24] Phase I and pharmacokinetic study of imatinib mesylate (Gleevec) and gemcitabine in patients with refractory solid tumors
    Ali, Yaqoob
    Lin, Yong
    Gharibo, Mecide M.
    Gounder, Murugesan K.
    Stein, Mark N.
    Lagattuta, Theodore F.
    Egorin, Merrill J.
    Rubin, Eric H.
    Poplin, Elizabeth A.
    CLINICAL CANCER RESEARCH, 2007, 13 (19) : 5876 - 5882
  • [25] Pharmacokinetic And Safety Profile Of Treprostinil Following Three-Times Daily Dosing Of Oral Treprostinil In Healthy Subjects
    Jenkins, A.
    Wang-Smith, L.
    Pham, T.
    Laliberte, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [26] Phase I and pharmacokinetic study of anhydrovinblastine every 3 weeks in patients with refractory solid tumors
    Nithya Ramnath
    Gary N. Schwartz
    Patrick Smith
    Daniel Bong
    Peter Kanter
    Joanne Berdzik
    Patrick J. Creaven
    Cancer Chemotherapy and Pharmacology, 2003, 51 : 227 - 230
  • [27] A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy
    Christopher Lieu
    Laura Chow
    A. Scott Pierson
    S. Gail Eckhardt
    Cindy L. O’Bryant
    Mark Morrow
    Zung Vu Tran
    John J. Wright
    Lia Gore
    Investigational New Drugs, 2009, 27 : 53 - 62
  • [28] PHASE-II STUDY OF DAILY ORAL ETOPOSIDE IN REFRACTORY GERM-CELL TUMORS
    MILLER, JC
    EINHORN, LH
    SEMINARS IN ONCOLOGY, 1990, 17 (01) : 36 - 39
  • [29] A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy
    Lieu, Christopher
    Chow, Laura
    Pierson, A. Scott
    Eckhardt, S. Gail
    O'Bryant, Cindy L.
    Morrow, Mark
    Tran, Zung Vu
    Wright, John J.
    Gore, Lia
    INVESTIGATIONAL NEW DRUGS, 2009, 27 (01) : 53 - 62
  • [30] A phase I study of ifosfamide, oxaliplatin, and etoposide (IOE) in pediatric patients with refractory solid tumors.
    McGregor, L. M.
    Spunt, S. L.
    Ward, D.
    Wu, J.
    Billups, C.
    Ivy, S. P.
    Santana, V. M.
    Fouladi, M.
    Furman, W. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345